B细胞特异性莫洛尼鼠白血病病毒整合位点1：上皮性卵巢癌的潜在分层因子和治疗靶点。
B-cell-specific Moloney murine leukemia virus integration site 1: potential stratification factor and therapeutic target for epithelial ovarian cancer.
作者信息
Zhao Qianying, Gui Ting, Qian Qiuhong, Li Lei, Shen Keng
机构信息
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing.
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Shandong, People's Republic of China.
出版信息
Onco Targets Ther. 2016 Aug 22;9:5203-8. doi: 10.2147/OTT.S109443. eCollection 2016.
Epithelial ovarian cancer, a vexing challenge for clinical management, still lacks biomarkers for early diagnosis, precise stratification, and prognostic evaluation of patients. B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1), a member of the polycomb group of proteins, engages in diverse cellular processes, including proliferation, differentiation, senescence, and stem cell renewal. In addition, BMI1, as a cancer stem-cell marker, participates in tumorigenesis through various pathways. Rewardingly, recent studies have also revealed a relationship between BMI1 expression and the clinical grade/stage, therapy response, and survival outcome in a majority of human malignancies, including epithelial ovarian cancer. Therefore, BMI1 might serve as a potential stratification factor and treatment target for epithelial ovarian cancer, pending evidence from further investigations.
上皮性卵巢癌是临床管理中一个棘手的挑战，目前仍缺乏用于早期诊断、精确分层以及患者预后评估的生物标志物。B细胞特异性莫洛尼氏鼠白血病病毒整合位点1（BMI1）是多梳蛋白家族的成员，参与多种细胞过程，包括增殖、分化、衰老和干细胞更新。此外，BMI1作为一种癌症干细胞标志物，通过多种途径参与肿瘤发生。值得庆幸的是，最近的研究还揭示了BMI1表达与大多数人类恶性肿瘤（包括上皮性卵巢癌）的临床分级/分期、治疗反应和生存结果之间的关系。因此，在获得进一步研究证据之前，BMI1可能作为上皮性卵巢癌的潜在分层因素和治疗靶点。
Zotero 插件